Clinical marker of platelet hyperreactivity in diabetes mellitus

Jin Hwa Kim1, Hak Yeon Bae1, Sang Yong Kim1

  • 1Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Korea.

Insights

Diabetic patients face higher risks of atherothrombotic events due to altered platelet function. Understanding these platelet abnormalities is key for managing diabetes complications and predicting cardiovascular events.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hematology

Background:

  • Diabetes mellitus is a significant risk factor for atherothrombotic complications, contributing to morbidity and mortality.
  • Diabetes is characterized by a prothrombotic state, involving increased coagulation, impaired fibrinolysis, endothelial dysfunction, and platelet hyperreactivity.
  • Altered platelet function is a critical factor in the prothrombotic status observed in diabetic patients.

Purpose of the Study:

  • To review the current understanding of platelet function abnormalities in diabetes.
  • To highlight the role of platelet hyperreactivity in diabetic atherothrombosis.
  • To discuss clinical markers associated with platelet hyperreactivity in diabetes.

Main Methods:

  • Literature review of studies on platelet function in diabetes.
  • Analysis of factors contributing to the prothrombotic state in diabetic patients.
  • Examination of clinical markers of platelet hyperreactivity.

Main Results:

  • Diabetes is associated with significant alterations in platelet function.
  • Platelet hyperreactivity is a key contributor to atherothrombotic events in diabetes.
  • Specific clinical markers reflect platelet hyperreactivity in diabetic individuals.

Conclusions:

  • Understanding platelet function abnormalities is crucial for managing diabetes-related cardiovascular risks.
  • Focusing on platelet function can improve the prediction and prevention of atherothrombotic events in diabetic patients.
  • Further research into platelet behavior in diabetes is warranted for therapeutic advancements.

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K